10-Q: TherapeuticsMD Reports First Quarter 2024 Results, Transitioning to Royalty-Based Model

TherapeuticsMD's first quarter 2024 results reflect its transition to a pharmaceutical royalty company, with a net loss of $734 thousand and a decrease in operating expenses.

Summary

• TherapeuticsMD reported a net loss of $734 thousand for the first quarter of 2024, compared to a net loss of $3.6 million in the same period of 2023.
• The company's revenue was $313 thousand, primarily from licensing agreements, down from $416 thousand in the first quarter of 2023.
• Operating expenses decreased significantly to $1.455 million, a 52.8% reduction compared to $3.083 million in the first quarter of 2023, due to the company's transition to a royalty-based model.
• The company's loss from continuing operations was $809 thousand, an improvement from the $2.31 million loss in the first quarter of 2023.
• Discontinued operations showed a net income of $75 thousand, compared to a net loss of $1.293 million in the first quarter of 2023.
• The company's cash and cash equivalents stood at $4.338 million as of March 31, 2024.
• TherapeuticsMD is currently engaged in a dispute with Mayne Pharma regarding the calculation of certain allowances related to their licensing agreement.
• The company has raised $3.15 million through a subscription agreement with Rubric Capital Management LP.

Sentiment

Score: 4

Explanation: The document shows a company in transition with improved financials but facing significant challenges, including a dispute with a key partner and potential liquidity issues. The need for additional capital raises concerns.

Positives

• The company's net loss significantly improved year-over-year, decreasing from $3.6 million to $734 thousand.
• Operating expenses were substantially reduced by 52.8%, reflecting the transition to a royalty-based model.
• The loss from continuing operations improved from $2.31 million to $809 thousand.
• Discontinued operations showed a net income of $75 thousand, a positive shift from a loss of $1.293 million in the prior year.
• The company has secured additional funding through a subscription agreement with Rubric Capital Management LP.

Negatives

• License revenue decreased from $416 thousand to $313 thousand year-over-year.
• The company is involved in a dispute with Mayne Pharma regarding allowance calculations, creating uncertainty.
• The company's cash reserves are relatively low at $4.338 million.
• The company may need to raise additional capital to fund operations.

Risks

• The company's ability to continue as a going concern is uncertain due to potential liquidity issues.
• The ongoing dispute with Mayne Pharma could have a material impact on the company's financial results.
• The company's reliance on royalty payments from licensees exposes it to risks related to their sales performance.
• The company may face challenges in securing additional financing if needed.
• The company's ability to sell equity securities may be limited by market conditions.

Future Outlook

The company may need to raise additional capital to fund operations until it becomes cash flow positive. The company is also focused on resolving the dispute with Mayne Pharma and monitoring the performance of its licensees.

Management Comments

• Management is monitoring the unresolved and pending net working capital items with Mayne Pharma.
• Management believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable.

Industry Context

The transition to a royalty-based model is a significant shift for TherapeuticsMD, reflecting a trend in the pharmaceutical industry where companies focus on core competencies and license out other aspects of their business. This move allows TherapeuticsMD to leverage the commercial capabilities of other companies while generating revenue from its intellectual property.

Comparison to Industry Standards

• TherapeuticsMD's transition to a royalty-based model is similar to other pharmaceutical companies that have divested commercial operations to focus on research and development or intellectual property management.
• The company's revenue is now primarily dependent on the sales performance of its licensees, which is a common model for companies that have licensed out their products.
• The dispute with Mayne Pharma is not uncommon in licensing agreements, where disagreements over financial terms and calculations can arise.
• The company's cash position is relatively low compared to other pharmaceutical companies, which may require additional capital raising.

Management Changes

Legal Proceedings

• The company is involved in a patent infringement lawsuit with Teva Pharmaceuticals regarding IMVEXXY.
• The company is in a dispute with Mayne Pharma regarding the calculation of certain allowances related to their licensing agreement.

Related Party Transactions

• The company has a subscription agreement with Rubric Capital Management LP, a related party, for the sale of common stock.
• A director of the company, Mr. Roberts, is a Partner of Rubric, but has elected not to receive compensation for his service as a non-employee director.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and uncertainty due to the ongoing dispute with Mayne Pharma.
• Employees are limited to one full-time employee, with external consultants supporting operations.
• Customers are not directly impacted as the company has transitioned to a royalty-based model.
• Suppliers are not directly impacted as the company has transitioned to a royalty-based model.
• Creditors may be impacted by the company's potential need for additional financing.

Next Steps

• The company will continue to monitor the performance of its licensees and the resolution of the dispute with Mayne Pharma.
• The company will explore options for raising additional capital to fund operations.
• The company will continue to evaluate changes to processes, information technology systems and other components of internal controls over financial reporting.

Key Dates

Keywords

royalty, licensing, pharmaceutical, TherapeuticsMD, financial results, net loss, operating expenses, Mayne Pharma, IMVEXXY, BIJUVA, ANNOVERA